Monday, October 27, 2025
- 10:30AM-12:30PM
-
Abstract Number: 0942
Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus
(0934–0954) Systemic Lupus Erythematosus – Animal Models Poster- 10:30AM-12:30PM
-
Abstract Number: 1455
Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 0929
SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice
(0916–0933) Innate Immunity Poster- 10:30AM-12:30PM
-
Abstract Number: 0962
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
(0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I- 10:30AM-12:30PM
-
Abstract Number: 1571
Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II- 10:30AM-12:30PM
-
Abstract Number: 0933
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
(0916–0933) Innate Immunity Poster- 10:30AM-12:30PM
-
Abstract Number: 1251
Steroids and Me (Sam): engaging and educating steroid-treated patients via patient advocacy partnerships and internet search channels.
(1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1069
Strengthening Rheumatology Workforce Capacity and Impact on Patient Care in Louisiana: Expanding Fellowship Training Opportunities Through Strategic Partnerships
(1055–1087) Healthcare Disparities in Rheumatology Posters- 10:30AM-12:30PM
-
Abstract Number: 1416
Structural Damage Progression in the Spine in Patients with Psoriatic Arthritis: Findings from a Longitudinal Cohort Study
(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1595
Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis
(1592–1611) Vasculitis – ANCA-Associated Poster II- 10:30AM-12:30PM
-
Abstract Number: 0955
Surveying RNA methylation in scleroderma highlights roles for demethylases ALKBH5 and FTO in fibrosis
(0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I- 10:30AM-12:30PM
-
Abstract Number: 1429
Survival Outcomes in Elderly Patients with Axial Spondyloarthritis and Concomitant Cancer
(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1465
Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 1613
Switching From Reference Tocilizumab to Biosimilar in Giant Cell Arteritis: Effectiveness and Safety in a Multicenter Study of 38 Patients